Innovent Biologics Inc - Asset Resilience Ratio

Latest as of December 2025: 2.37%

Innovent Biologics Inc (6IB) has an Asset Resilience Ratio of 2.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€886.74 Million

≈ $1.04 Billion USD Cash + Short-term Investments

Total Assets

€37.35 Billion

≈ $43.66 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Innovent Biologics Inc's Asset Resilience Ratio has changed over time. Check 6IB strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Innovent Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Innovent Biologics Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€886.74 Million	2.37%
Total Liquid Assets	€886.74 Million	2.37%

Asset Resilience Insights

Limited Liquidity: Innovent Biologics Inc maintains only 2.37% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Innovent Biologics Inc Industry Peers by Asset Resilience Ratio

Compare Innovent Biologics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Innovent Biologics Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Innovent Biologics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.37%	€886.74 Million ≈ $1.04 Billion	€37.35 Billion ≈ $43.66 Billion	+0.64pp
2024-12-31	1.74%	€375.56 Million ≈ $439.06 Million	€21.60 Billion ≈ $25.26 Billion	-34.01pp
2023-12-31	35.75%	€7.37 Billion ≈ $8.62 Billion	€20.63 Billion ≈ $24.12 Billion	-5.46pp
2022-12-31	41.21%	€7.25 Billion ≈ $8.47 Billion	€17.59 Billion ≈ $20.56 Billion	+37.24pp
2021-12-31	3.97%	€644.85 Million ≈ $753.90 Million	€16.24 Billion ≈ $18.99 Billion	+0.95pp
2020-12-31	3.02%	€357.30 Million ≈ $417.72 Million	€11.83 Billion ≈ $13.84 Billion	-28.37pp
2019-12-31	31.39%	€2.27 Billion ≈ $2.65 Billion	€7.23 Billion ≈ $8.45 Billion	-1.56pp
2017-12-31	32.94%	€809.48 Million ≈ $946.37 Million	€2.46 Billion ≈ $2.87 Billion	+5.16pp
2016-12-31	27.78%	€782.25 Million ≈ $914.53 Million	€2.82 Billion ≈ $3.29 Billion	--

pp = percentage points

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$19.20 Billion

€16.42 Billion EUR

Market Cap Rank

#1481 Global

#332 in Germany

Share Price

€9.47

Change (1 day)

-2.63%

52-Week Range

€7.96 - €11.60

All Time High

€11.80